Separately, Zacks Investment Research lowered shares of Humacyte from a “buy” rating to a “hold” rating in a research note on Saturday, April 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $13.65.
NASDAQ HUMA traded up $0.33 on Friday, reaching $5.37. 534,060 shares of the company’s stock traded hands, compared to its average volume of 315,771. The company has a quick ratio of 20.75, a current ratio of 20.75 and a debt-to-equity ratio of 0.40. The stock has a 50-day simple moving average of $6.60 and a 200 day simple moving average of $7.33. Humacyte has a 12 month low of $4.37 and a 12 month high of $17.45.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Penserra Capital Management LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Citigroup Inc. bought a new stake in Humacyte during the third quarter valued at about $47,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in Humacyte during the first quarter valued at about $48,000. Bank of America Corp DE grew its holdings in Humacyte by 96.7% during the fourth quarter. Bank of America Corp DE now owns 6,887 shares of the company’s stock valued at $51,000 after purchasing an additional 3,385 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in Humacyte during the fourth quarter valued at about $73,000. 9.25% of the stock is currently owned by hedge funds and other institutional investors.
About Humacyte (Get Rating)
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).
- Get a free copy of the StockNews.com research report on Humacyte (HUMA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.